Latest Period
Q2 2026
Security Snapshot
Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) Institutional Ownership
CUSIP: 87975F104
13F Institutional Holders and Ownership History from Q1 2024 to Q2 2026
Institutions Reporting
32
Shares (Excl. Options)
2,965,031
Price
$1.28
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, no par value
- Symbol
- TELO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,965,031
- Total 13F value
- $3,795,556
- Portfolio coverage rank
- 0%
- Share change
- +724,758
- Value change
- +$922,651
- Number of holders
- 32
- Shares outstanding
- 68,772,896
- SEC-reported price per share
- $1.25
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value is tracked under CUSIP 87975F104.
- 32 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 27 to 32 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,913,054 to $3,795,556.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 32 institutions filings for Q2 2026.
Security key
87975F104
Latest holder period
Q2 2026
13F holders
32
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
TELO full holder history
Telomir Pharmaceuticals, Inc. SEC filings
Telomir Pharmaceuticals, Inc. company facts
Telomir Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87975F104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
TELO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| DEJORIA JOHN PAUL | 5.2% | -47% | $4,514,686 | +$393,536 | 3,554,871 | +9.5% | John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity | 30 Jun 2026 |
As of 30 Jun 2026, 32 institutional investors reported holding 2,965,031 shares of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO). This represents 4.3% of the company’s total 68,772,896 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q2 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 2,965,031 | $3,795,556 | +$922,651 | $1.28 | 32 |
| 2026 Q1 | 2,240,278 | $2,913,054 | -$60,349 | $1.30 | 27 |
| 2025 Q4 | 2,285,727 | $3,040,166 | -$68,478 | $1.33 | 33 |
| 2025 Q3 | 2,332,205 | $3,240,559 | -$616,944 | $1.39 | 31 |
| 2025 Q2 | 2,807,449 | $3,509,640 | -$1,509,843 | $1.25 | 42 |
| 2025 Q1 | 3,692,775 | $11,927,929 | +$377,557 | $3.23 | 42 |
| 2024 Q4 | 3,563,053 | $14,680,234 | +$6,102,927 | $4.12 | 37 |
| 2024 Q3 | 2,045,931 | $13,136,057 | +$9,006,860 | $6.42 | 33 |
| 2024 Q2 | 361,326 | $1,737,881 | +$1,328,649 | $4.81 | 24 |
| 2024 Q1 | 79,917 | $413,466 | +$413,466 | $5.15 | 7 |